EyePoint Pharmaceuticals Inc (EYPT)

[jupp]

Long-acting ILUVIEN implant is now available to reduce the number of eye injections patients need
Posted March 19th, 2015 by Priority Marketing

Retina Health Center now offers ILUVIEN, a new treatment for diabetic macular edema recently approved by the U.S. Food and Drug Administration (FDA).

...According to Eaton, the response of patients has been overwhelmingly positive. Prior to the approval of the ILUVIEN implant, patients typically required treatments every one to three months with Avastin, Lucentis, Eylea, Ozurdex and Triamcinolone. For patients receiving treatment with these older options, which are done by injecting a medication into the patients’ eye, the prospect of reducing the number of treatments from 36 to 1, in the best case scenario, to somewhere in between in patients with more advanced disease, is a positive one.


www.southwestfloridamarketingforum.com/?p=6220